TorreyPines Therapeutics Completes Phase I Trial of NGX267
TorreyPines Therapeutics announced completion of its third Phase I clinical trial for NGX267 for the treatment of cognitive impairment associated with schizophrenia.
According to TorreyPines, the compound, a functionally selective muscarinic agonist, was found to be safe and well-tolerated when given orally to healthy male volunteers.
A total of 60 healthy males between the ages of 18 and 55 were enrolled in the double-blind, placebo-controlled trial conducted in Belgium. In a series of sequential dosing groups, subjects received a single oral dose of either 10, 20, 30 or 35 mg of NGX267 once daily for four consecutive days.
NGX267 was well-tolerated at doses up to 30 mg, a dose range believed to be effective for treating memory and cognitive disturbances, the company said.
In two previous Phase I trials, NGX267, administered as single oral doses, was shown to be well tolerated in healthy young adult males, as well as in healthy elderly males and females, the company added.